aero therapeutics

We help physicians in low-resource settings treat neonatal respiratory issues with our sustainable, rugged and affordable devices.



15+ million

babies are born prematurely per year and these rates are **increasing** globally.

1.1 million

babies die each year due to complications of preterm birth

SDG 3.2:

By 2030, end preventable deaths of newborns and children under 5 years of age, with all countries aiming to reduce neonatal mortality to at least as low as 12 per 1,000 live births and under-5 mortality to at least as low as 25 per 1,000 live births.

We are currently <u>not</u> on track to meet this goal by 2030.

Standard of Care

for premature respiratory distress is often reused water bottles.

Our S-HHFNC Final Prototype

- Oxygenates, warms, humidifies, and **sterilizes** air before it is delivered in a single, compact, and mobile enclosure.



PCT Filed 23Aug2019: 047162-5227-P3US
Patent Title: PORTABLE AND COMPACT SYSTEM FOR DELIVERY OF HUMIDIFIED HIGH FLOW NASAL CANNULA (HHFNC) THERAPY IN NEONATES AND INFANTS

Secured past financial support:

USAID

SAVING LIVES AT BIRTH: A GRAND CHALLENGE FOR DEVELOPMENT

VENTUREWELL™ idea to impact

Bench Testing of Final Prototype

- Developed iteratively in Ethiopia.
- Aero device demonstrates comparable performance with commercially available devices at ~1/10th the cost.







Management Team

Anjelica Gonzalez, PhD
Founder + Inventor

Engineer focused on the development of biomaterials for use as investigational tools, immunological responses to inflammatory signals from endogenous and exogenous sources.

Yale

Baylor College of Medicine

Jamison Langguth, MPH, MSED
Co-founder

Social entrepreneur focused on impact with eight years of clinical operations experience managing nation-wide first-in-human clinical trials.

Yale

Penn
University of Pennsylvania

HARVARD UNIVERSITY

Sten Vermund, MD, PhD
Mentor

Pediatrician and infectious disease epidemiologist focused on diseases of low and middle income countries.

Yale

Stanford University

Columbia University
In the City of New York

Addressable Market – Preterm Respiratory Distress



Phase I

Ethiopia
200+ Hospitals

15% Reduction of Neonatal Deaths
Potential Lives Saved Yearly: 52,880

Phase II

India
20,000+ Hospitals

15% Reduction of Neonatal Deaths
Potential Lives Saved Yearly: 448,428

Financial Projection

Total sales for Aero devices

USD million, 2020E-2025E



Net income

USD million, 2020E-2025E



	2020E	2021E	2022E	2023E	2024E	2025E
Revenue (USD Million)	4	8	17	38	83	181
EBITDA (USD Million)	1	2	5	11	24	54
EBITDA Margin	21%	25%	27%	29%	29%	30%
Sales per client (USD 000)	9.4	8.9	9.9	11.0	12.3	13.7

Competition

	Surfactant Monotherapy	HHFNC (Optiflow)	CPAP	Improvised Care (Water Bottles)	Pumani (bCPAP)	Vapotherm (Precision Flow+)	Our S-HHFNC Device
							
Humidified	X	✓	X	X	X	✓	✓
Warmed	X	✓	X	X	X	✓	✓
Auto H2O Sterilization	X	X	X	X	X	X	✓
Safe	?	✓	✓	X	✓	✓	✓
Local Parts	X	X	X	X	X	X	✓
Price (USD)	$1140-2280	$5,000	$1000-$3000	Low	~$900	~$1,500	$500

Competition

CPAP

HHFNC

Market Size of Future Indications



Timeline



Exit Strategy (5-year)

Acquisition by global
med-tech co

Medtronic

Fisher & Paykel HEALTHCARE

Boston Scientific

www.breatheaero.com